Roka Bioscience — Investor Presentation (September 2016)
30 slides from Roka Bioscience's investor presentation, Sep 16, 2016
Slide 1: Roka Bioscience June 2016
CONFIDENTIAL ROKA BIOSCIENCE June 2016
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CONFIDENTIAL Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended
Slide 3: Key Highlights
CONFIDENTIAL Key Highlights Founded in 2009 via acquisition of the industrial testing assets of Gen-Probe, a global leader in molecular diagnostics Pure Play in Growing $2 Billion Food Safety Market* IPO completed in July 2014 Early Adoption By Strategic Customers Full Menu of Molecular Path
Slide 4: Food Safety Testing: $2 Billion Global Market
CONFIDENTIAL Food Safety Testing: $2 Billion Global Market Source: Capella Advisors, Company Estimates Food Safety Testing Market 4
Slide 5: North American Market Growth in Molecular Testing
CONFIDENTIAL North American Market Growth Market in Molecular Testing Market Growth Driven by Conversion to Molecular Test Volume: 75 Million SCI Food Micro 5, May 2011 & Food Micro 8 June 2013, Internal estimates ASP assumptions: Molecular $8.00/test, Antibody $5.00/test, Traditional $3.00/test 5 $
Slide 6: North American Pathogen Testing Locations
CONFIDENTIAL North American Pathogen Testing Locations Food Safety Testing Market 45 M 30 M Food Processors 3rd Party Pathogen Tests by Location 3rd Party Lab Market • Outpacing market growth • Move due to liability, technology & cost Current Testing Lab Landscape • 300-400 small labs • Fragmented
Slide 7: Our food needs to be safer
CONFIDENTIAL Each year the CDC reports: 48 Million sick 128,000 Hospitalized 3,000 Dead As healthier eating continues: Increased raw fruits & veggies Less over-cooked foods An expectation of local and healthy Unless something changes, there will be more outbreaks, similar to Chipot
Slide 8: Technology adoption has not happened....why?
CONFIDENTIAL Finding pathogens means additional cost of operations, e.g. diverting product, cleaning facilities, etc. Most used environmental tests (antibody-based) misses up to 50% of pathogenic bacteria* Consistent negative results satisfied regulators until now Rarely caught for poor testing,
Slide 9: Processors are now caught for poor testing
CONFIDENTIAL Processors are now caught for poor testing NEW ability to trace illness back to food 9 FSMA mandated prevention-based controls in all food processors 2015 & 2016 starts the enforcement phase Beginning in 2013 the CDC utilizes Whole Genome Sequencing (WGS) to build database to trac
Slide 10: WGS will be a change agent for the industry
CONFIDENTIAL WGS will be a change agent for the industry Listeria WGS launched in 2013; Salmonella, others to follow Testing to get a negative is no longer acceptable 10 Whole Genome Sequencing Impact 6 to 93 cases linked to food source in first 2 years Traceability: Now linking outbreak to sp
Slide 11: Processors want to stay out of the news
CONFIDENTIAL Processors want to stay out of the news Representative Food borne Disease Outbreaks (2011- 2016) Product: Salad Mixes Ingredients Ice Cream Apples Chicken Peanut Butter Ground Turkey Pathogen: L. Mono STEC 026 L. Mono L. Mono Salmonella Salmonella Salmonella Case Count: 19 55 10 35 634
Slide 12: Commercial Timeline
CONFIDENTIAL Commercial Timeline Contamination issue with Listeria encountered Q3-2014 – Significant impact on stock price and valuation Re-development of Listeria assay – Increased robustness of assay, allowing handling by labs – Commercial launch late 2015 Commercial status – Con-Agra evalua
Slide 13: Relaunch with full suite of high quality assays
CONFIDENTIAL Relaunch with full suite of high quality assays Listeria – NEW assay Salmonella E. coli O157:H7 Listeria Monocytogenes Shiga toxin-producing E. coli (STEC) Atlas Detection AssaysAtlas Instrument Full Commercial Menu Roka Value Proposition Accurate, Rapid, Fully-Automated Test
Slide 14: Proprietary Technology with Full Automation
CONFIDENTIAL Proprietary Technology with Full Automation • Walkaway Functionality • Incorporated Process Controls • Continuous flow processing • High Throughput Capability • Removes Operator Variability Purification Target Capture Amplification TMA Detection HPA • Integrated molecular Clean Up • Rap
Slide 15: Revenue Model
CONFIDENTIAL - 50 100 150 200 250 300 350 400 Q1-2016 Average Q1-2016 High Revenue Model Targeting labs with 75-150 tests per day Instruments typically placed as reagent rental Cost of instrument recovered through consumables sales Significant revenue opportunity per instrument placed 15 *Ba
Slide 16: Commercial Success to Date
CONFIDENTIAL Commercial Success to Date 16 DoD Food Analysis & Diagnostics Laboratory *Actual customers *
Slide 17: Commercial Strategy
CONFIDENTIAL Commercial Strategy Capitalize on new market drivers Drive a segment focused organization Focused promotional activities • Listeria Environmental Monitoring – all markets • Capitalize on processors fear of WGS Key Strategic Initiatives • Partnership with significant third party
Slide 18: How to Win in the Lab Market
CONFIDENTIAL How to Win in the Lab Market Sample Pick-Up Logistics Leverage Existing Food Safety Business Strong Balance Sheet Efficient Lab Operations Automation, flexibility High volume, scalable instruments Direct labor reductions 18 Enabled by Roka’s Atlas
Slide 19: Significant Lab Partnership Opportunity to Drive Market
CONFIDENTIAL Significant Lab Partnership Opportunity to Drive Market Competitive pricing of molecular tests Competitors will experience price erosion or lose business Leverage existing courier infrastructure for national coverage Offer a fast turn around time, despite shipping Lab efficie
Slide 20: Atlas Pathogen Test Pricing by Lab
CONFIDENTIAL Atlas Pathogen Test Pricing by Lab 45.2 M 30.2 M 4% 31% 65% Target ASP of ~ $18.00 for an Atlas pathogen test result would be an attractive and disruptive force in 3rd party testing market Margin opportunity for both lab partner and Roka 20
Slide 21: Third Party Lab Opportunity 2016-2019 Lab Revenue Potential
CONFIDENTIAL Third Party Lab Opportunity 2016-2019 Lab Revenue Potential Illustration of opportunity to build significant revenue for lab partner* 21 * Environmental Listeria volume only. Company estimates Assuming lab charges $18 price per test to its customers Year 1 Year 2 Year 3 Year 4 10% 44
Slide 22: Laboratory Business Profitability
CONFIDENTIAL $18 test price to end customers Lab gross margin >35% Exceeds current business 33% margin Laboratory Business Profitability 22 Roka gross margin >40% on sales to lab Roka pricing to lab discounted for large volume Meaningful margins for both lab and Roka
Slide 23: Third Party Lab Opportunity 2016 Objectives
CONFIDENTIAL Third Party Lab Opportunity 2016 Objectives Q1 – Atlas units into partner laboratory Q2/Q3 – Pilot Concept Pricing model Courier Atlas volume Q4 – Agreement Initiate broader roll-out 23
Slide 24: Current Pathogen Testing in the Beef Industry
CONFIDENTIAL Current Pathogen Testing in the Beef Industry Testing Opportunity 3.8 0.5 4.3M Pathogen Tests* E. coli 0157:H7 Salmonella/STEC Incumbent Technology BioControl GDS Regulatory Environment E. coli O157:H7 and Big Six STEC adulterants 24 *FSIS 2013 Pathogen Controls in Beef Survey, Company
Slide 25: Pathway to Market Adoption
CONFIDENTIAL Pathway to Market Adoption Roka engaged with leading beef processor over the past two years to meet external & internal adoption requirements Gain Atlas Adoption by one of the Big Four Beef Producers 25
Slide 26: Current Status
CONFIDENTIAL Current Status Customer already uses Atlas for all Poultry testing and recognizes efficiencies Industry conservative on making testing change due to recent litigations on E.Coli O157:H7 Risk of change offset by significant cost savings benefit Significant cost savings estimated by
Slide 27: Beef Market Opportunity
CONFIDENTIAL Beef Market Opportunity 27 3.8 0.5 4.3M Pathogen Tests E. coli 0157:H7 Salmonella/STEC 4 large processors *Revenue based on $8.00 per test Revenue ($ mill.)* 25% 9 50% 17 75% 26 100% 34 Sh ar e FSIS 2013 Pathogen Controls in Beef Survey, Company Estimates
Slide 28: Funding Summary
CONFIDENTIAL Funding Summary Well positioned to benefit from a changing food safety market Lab partnership and beef present exciting opportunities $25M Financing sought to fund significant revenue growth Insider participation by leading investors 28
Slide 29: Cap Table March 31, 2016
CONFIDENTIAL Cap Table March 31, 2016 52% 29 Shares outstanding (millions) 17.9 100% OrbiMed 3.2 18% NEA 3.2 18% TPG 2.9 16% Other insiders 1.0 6% Craig Drill 1.6 9% Hologic 0.9 5% Aisling 0.5 3% Others 4.5 25%
Slide 30: Balance Sheet Summary
CONFIDENTIAL Balance Sheet Summary $25.5 working capital $3.0 debt principal due by end of 2016 ($ Million) 31-Mar-16 Cash and equivalents 23.3 Property and equipment 9.4 Intangible assets 21.5 Other assets 10.0 Debt 9.0 Deferred payments 4.1 Other liabilities 13.9 Equity 37.2 30
Roka BioScience — Investor Presentation (September 2016) on 6ix